HydroxyCitric Acid / HO-1 Cancer Research Results

HCA, HydroxyCitric Acid: Click to Expand ⟱
Features:
HCA is a naturally occurring compound primarily known for its potential effects on appetite and lipid metabolism via inhibition of ATP citrate lyase.
Derivative of citric acid that is found in a variety of tropical plants including Garcinia cambogia and Hibiscus sabdariffa
Hydroxycitric acid (HCA) is a plant‐derived hydroxycinnamic acid derivative best known for inhibiting ATP citrate lyase (ACLY), a key enzyme that generates cytosolic acetyl-CoA from citrate for lipid and cholesterol synthesis. By reducing ACLY activity and downstream lipogenesis, HCA shifts cellular metabolism and can activate energy-sensing pathways (such as AMPK) in some models. Evidence for direct anticancer cytotoxicity is modest and often linked to metabolic stress rather than primary cytotoxic mechanisms. Oral exposure is influenced by rapid metabolism and conjugation, with systemic bioavailability often limited compared to levels used in many in vitro studies.

• Hydroxy-Citric Acid (HCA) is a compound extracted from Garcinia cambogia, primarily recognized for its potential effects on lipid metabolism and appetite suppression.
• It has been proposed to inhibit the enzyme ATP citrate lyase, which is involved in converting citrate into acetyl-CoA—a key step in fatty acid synthesis.
• By modulating lipid synthesis pathways, HCA has been studied in the context of obesity and metabolic disorders, with some exploratory research considering its implications in cancer metabolism.

• Inhibition of ATP Citrate Lyase (ACLY)******
ACLY converts citrate into acetyl-CoA, a building block for fatty acid and cholesterol synthesis. Many cancer cells upregulate lipid synthesis to support membrane production and energy storage; hence, inhibiting ACLY presents a potential strategy to disrupt cancer cell metabolism.

• Impact on Lipogenesis
Reduced acetyl-CoA production can impair de novo lipogenesis, potentially limiting the proliferation of rapidly dividing cells that have high lipid demands.

• Interactions with Other Metabolic Pathways (modulation of citrate levels may affect the TCA cycle)

-Dosages used in weight loss studies typically ranging from 500 mg to 1500 mg per day
Human cyclists: 3.1 mL/kg body wt of an HCA solution (19 g/L) --> 248mg
"Studies have shown that humans can safely ingest 13.5 g of hydroxycitrate per day with plasma levels of 82 mg/L (0.39 mM) achieved". Appetite suppression and weight loss effects are mixed.
Typically, HCA used in dietary weight loss supplement is bound to calcium, which results in a poorly soluble (<50%) and less bioavailable form. Conversely, the structural characteristics of a novel Ca2+/K+ bound (-)-HCA salt (HCA-SX or Super CitriMax) make it completely water soluble as well as bioavailable.

-HydroxyCitrate (HCA) typically used in a dose of about 1.5g/day or more for cancer (inhibition of the Melavonate Pathway?)

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 ATP citrate lyase (ACLY) inhibition ACLY ↓ (reported; model-dependent) Energy metabolism modulation P, R, G Lipid synthesis constraint HCA interferes with ACLY, reducing cytosolic acetyl-CoA used for lipogenesis; this is the most direct biochemical target supported in metabolic studies.
2 Fatty acid synthesis / lipogenesis pathways FAS ↓; lipogenic genes ↓ (reported) Lipid synthesis modulation R, G Metabolic shift Downstream of ACLY inhibition; reduced fatty acid and cholesterol precursor synthesis is the central metabolic effect.
3 AMPK activation (energy sensor, model-dependent) AMPK ↑ (reported) Energy homeostasis support R, G Energy balance modulation AMPK activation is observed in some in-vitro systems with HCA, linking energy stress to downstream metabolic effects.
4 Appetite / satiety signaling (neuropeptides) — Appetite modulation (reported) G Metabolic/behavioral Some human studies suggest appetite/satiety modulation but evidence is mixed; include as “reported” not primary anticancer mechanism.
5 Insulin / glucose metabolism signaling Modulation reported (trend) Insulin sensitivity influence (reported) G Metabolic adjustment Some systematic models report modest effects on insulin and glucose handling; these are downstream metabolic observations, not direct anticancer targets.
6 NF-κB inflammatory transcription Modest ↓ reported (context) Inflammation modulation (reported) R, G Anti-inflammatory trend Some preclinical models link metabolic improvement to reduced inflammation; not a robust anticancer signal alone.
7 Cell proliferation / apoptosis Modulation reported in some tumor models ↔ G Conditional growth modulation Isolated in vitro studies show modest proliferation changes; evidence is far weaker and often linked to metabolic stress rather than direct cytotoxicity.
8 PI3K/AKT / survival kinase signaling Reported modulation (weak / context) ↔ R, G Growth signaling adaptation Reported downstream of metabolic modulation in some models; not a primary target like ACLY.
9 Invasion / metastasis programs (MMPs / EMT) Reports exist but inconsistent ↔ G Phenotype outcomes Largely phenotype-level readouts in select cell lines; not a consistent mechanistic anchor.
10 Bioavailability / metabolism constraint (rapid conjugation; limited systemic exposure) Systemic exposure variable; phase II metabolism — — Translation constraint HCA is absorbed but rapidly metabolized/conjugated; systemic levels after oral intake are relatively low compared to many in vitro assay doses.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid biochemical effects such as ACLY engagement)
  • R: 30 min–3 hr (acute metabolic signaling / transcription shifts)
  • G: >3 hr (transcriptional adaptation and phenotype outcomes)
HO-1, HMOX1: Click to Expand ⟱
Source:
Type:
(Also known as Hsp32 and HMOX1)
HO-1 is the common abbreviation for the protein (heme oxygenase‑1) produced by the HMOX1 gene.
HO-1 is an enzyme that plays a crucial role in various cellular processes, including the breakdown of heme, a toxic molecule. Research has shown that HO-1 is involved in the development and progression of cancer.
-widely regarded as having antioxidant and cytoprotective effects
-The overall activity of HO‑1 helps to reduce the pro‐oxidant load (by degrading free heme, a pro‑oxidant) and to generate molecules (like bilirubin) that can protect cells from oxidative damage

Studies have found that HO-1 is overexpressed in various types of cancer, including lung, breast, colon, and prostate cancer. The overexpression of HO-1 in cancer cells can contribute to their survival and proliferation by:
  Reducing oxidative stress and inflammation
  Promoting angiogenesis (the formation of new blood vessels)
  Inhibiting apoptosis (programmed cell death)
  Enhancing cell migration and invasion
When HO-1 is at a normal level, it mainly exerts an antioxidant effect, and when it is excessively elevated, it causes an accumulation of iron ions.

A proper cellular level of HMOX1 plays an antioxidative function to protect cells from ROS toxicity. However, its overexpression has pro-oxidant effects to induce ferroptosis of cells, which is dependent on intracellular iron accumulation and increased ROS content upon excessive activation of HMOX1.

-Curcumin   Activates the Nrf2 pathway leading to HO‑1 induction; known for its anti‑inflammatory and antioxidant effects.
-Resveratrol  Induces HO‑1 via activation of SIRT1/Nrf2 signaling; exhibits antioxidant and cardioprotective properties.
-Quercetin   Activates Nrf2 and related antioxidant pathways; contributes to anti‑oxidative and anti‑inflammatory responses.
-EGCG     Promotes HO‑1 expression through activation of the Nrf2/ARE pathway; also exhibits anti‑inflammatory and anticancer properties.
-Sulforaphane One of the most potent natural HO‑1 inducers; triggers Nrf2 nuclear translocation and upregulates a battery of phase II detoxifying enzymes.
-Luteolin    Induces HO‑1 via Nrf2 activation; may also exert anti‑inflammatory and neuroprotective effects in various cell models.
-Apigenin   Has been reported to induce HO‑1 expression partly via the MAPK and Nrf2 pathways; also known for anti‑inflammatory and anticancer activities.
Scientific Papers found: Click to Expand⟱
1633- HCA,    Hydroxycitric Acid Alleviated Lung Ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis through the Hif-1α Pathway
- in-vivo, NA, NA - in-vitro, Nor, HUVECs
*other↓, *Inflam↓, *MDA↓, *ROS↓, *Iron↓, *SOD↓, *Hif1a↓, *HO-1↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

HO-1↓, 1,   Iron↓, 1,   MDA↓, 1,   ROS↓, 1,   SOD↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  
Total Targets: 8

Scientific Paper Hit Count for: HO-1, HMOX1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:96  Target#:597  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page